Luminescent multiplex viability assay for Trypanosoma brucei gambiense

Parasites and Vectors

Volumn 6, Issue 1, 2013, Pages

  Van Reet, Nick ^a   Pyana, Pati ^a,b   Rogé, Stijn ^a   Claes, Filip ^a   Büscher, Philippe ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b Institut National de Recherche Biomedicale   (Congo)

Author keywords

Democratic Republic of the Congo; Luminescence; Multiplex; Renilla luciferase; Trypanosoma brucei gambiense; Viability

Indexed keywords

ADENOSINE TRIPHOSPHATE; EFLORNITHINE; MELARSOPROL; NIFURTIMOX; PENTAMIDINE; RENILLA LUCIFERIN 2 MONOOXYGENASE; RESAZURIN;

ARTICLE; BIOLUMINESCENCE; CELL DENSITY; CORRELATION ANALYSIS; ENZYME ACTIVITY; IC 50; LIMIT OF DETECTION; LUMINESCENT MULTIPLEX VIABILITY ASSAY; MICROBIAL SENSITIVITY TEST; NONHUMAN; TRYPANOSOMA; WILD TYPE;

ADENOSINE TRIPHOSPHATE; ANTIPROTOZOAL AGENTS; CELL SURVIVAL; INHIBITORY CONCENTRATION 50; LUCIFERASES, RENILLA; LUMINESCENT MEASUREMENTS; PARASITIC SENSITIVITY TESTS; PARASITOLOGY; RECOMBINANT PROTEINS; STAINING AND LABELING; TRYPANOSOMA BRUCEI GAMBIENSE;

RENILLA LUCIFERASE; TRYPANOSOMA BRUCEI GAMBIENSE;

EID: 84880085785     PISSN: None     EISSN: 17563305     Source Type: Journal    
DOI: 10.1186/1756-3305-6-207     Document Type: Article

References (50)

1. The human african trypanosomiasis control and surveillance programme of the world health organization 2000-2009: the way forward. Simarro PP, Diarra A, Ruiz Postigo JA, Franco JR, Jannin JG, PLoS Negl Trop Dis 2011 5 1007 10.1371/journal.pntd.0001007 21364972
2. Passage of parasites across the blood-brain barrier. Masocha W, Kristensson K, Virulence 2012 3 202 212 22460639
3. The development of drugs for treatment of sleeping sickness: a historical review. Steverding D, Parasit Vectors 2010 3 15 10.1186/1756-3305-3-15 20219092
4. Antiparasitic agents: new drugs on the horizon. Mäser P, Wittlin S, Rottmann M, Wenzler T, Kaiser M, Brun R, Curr Opin Pharmacol 2012 12 562 566 10.1016/j.coph.2012.05.001 22652215
5. High-throughput analysis of an RNAi library identifies novel kinase targets in Trypanosoma brucei. Mackey ZB, Koupparis K, Nishino M, McKerrow JH, Chem Biol Drug Des 2011 78 454 463 10.1111/j.1747-0285.2011.01156.x 21668652
6. Antiprotozoal and cytotoxic screening of 45 plant extracts from Democratic Republic of Congo. Mesia GK, Tona GL, Nanga TH, Cimanga RK, Apers S, Cos P, Maes L, Pieters L, Vlietinck AJ, J Ethnopharmacol 2008 115 409 415 10.1016/j.jep.2007.10.028 18068320
7. A luciferase based viability assay for ATP detection in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427. Sykes ML, Avery VM, Parasit Vectors 2009 2 54 10.1186/1756-3305-2-54 19909542
8. Development of an Alamar Blue viability assay in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427. Sykes ML, Avery VM, AmJTrop Med Hyg 2009 81 665 674 10.4269/ajtmh.2009.09-0015
9. Identification of a kappa-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis. Jones DC, Hallyburton I, Stojanovski L, Read KD, Frearson JA, Fairlamb AH, Biochem Pharmacol 2010 80 1478 1486 10.1016/j.bcp.2010.07.038 20696141
10. Mining a cathepsin inhibitor library for new antiparasitic drug leads. Ang KK, Ratnam J, Gut J, Legac J, Hansell E, Mackey ZB, Skrzypczynska KM, Debnath A, Engel JC, Rosenthal PJ, et al. PLoS Negl Trop Dis 2011 5 1023 10.1371/journal.pntd.0001023 21572521
11. Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors. Brand S, Cleghorn LA, McElroy SP, Robinson DA, Smith VC, Hallyburton I, Harrison JR, Norcross NR, Spinks D, Bayliss T, et al. J Med Chem 2012 55 140 152 10.1021/jm201091t 22148754
12. Hit-to-lead development of the chamigrane endoperoxide merulin A for the treatment of African sleeping sickness. Navarro G, Chokpaiboon S, De MG, Bray WM, Nisam SC, McKerrow JH, Pudhom K, Linington RG, PLoS One 2012 7 46172 10.1371/journal.pone.0046172 23029428
13. Application of a resazurin-based high-throughput screening assay for the identification and progression of new treatments for human African trypanosomiasis. Bowling T, Mercer L, Don R, Jacobs R, Nare B, Int J Parasitol Drugs Drug Resist 2012 2 262 270
14. A static-cidal assay for Trypanosoma brucei to aid hit prioritisation for progression into drug discovery programmes. De Rycker M, O'Neill S, Joshi D, Campbell L, Gray DW, Fairlamb AH, PLoS Negl Trop Dis 2012 6 1932 10.1371/journal.pntd.0001932 23209868
15. In vitro and in vivo activities of trybizine hydrochloride against various pathogenic trypanosome species. Kaminsky R, Brun R, Antimicrob Agents Chemother 1998 42 2858 2862 9797216 (Pubitemid 28501216)
16. New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289. Wenzler T, Boykin DW, Ismail MA, Hall JE, Tidwell RR, Brun R, Antimicrob Agents Chemother 2009 53 4185 4192 10.1128/AAC.00225-09 19620327
17. Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system African trypanosomiasis. Nare B, Wring S, Bacchi C, Beaudet B, Bowling T, Brun R, Chen D, Ding C, Freund Y, Gaukel E, et al. Antimicrob Agents Chemother 2010 54 4379 4388 10.1128/AAC.00498-10 20660666
18. Fexinidazole-a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. Torreele E, Bourdin TB, Tweats D, Kaiser M, Brun R, Mazue G, Bray MA, Pecoul B, PLoS Negl Trop Dis 2010 4 923 10.1371/journal.pntd.0000923 21200426
19. SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis. Jacobs RT, Nare B, Wring SA, Orr MD, Chen D, Sligar JM, Jenks MX, Noe RA, Bowling TS, Mercer LT, et al. PLoS Negl Trop Dis 2011 5 1151 10.1371/journal.pntd.0001151 21738803
20. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Kaiser M, Bray MA, Cal M, Bourdin TB, Torreele E, Brun R, Antimicrob Agents Chemother 2011 55 5602 5608 10.1128/AAC.00246-11 21911566
21. Differential susceptibility to DL-alpha-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense. Bacchi CJ, Nathan HC, Livingston T, Valladares G, Saric M, Sayer PD, Njogu AR, Clarkson AB Jr, Antimicrob Agents Chemother 1990 34 1183 1188 10.1128/AAC.34.6.1183 2118325 (Pubitemid 20177377)
22. Isolation and propagation of Trypanosoma brucei gambiense from sleeping sickness patients in south Sudan. Maina NW, Oberle M, Otieno C, Kunz C, Maeser P, Ndung'u JM, Brun R, Trans R Soc Trop Med Hyg 2007 101 540 546 10.1016/j.trstmh.2006.11.008 17275053 (Pubitemid 46613461)
23. Isolation of Trypanosoma brucei gambiense from cured and relapsed sleeping sickness patients and adaptation to laboratory mice. Pyana PP, Ngay Lukusa I, Mumba Ngoyi D, Van Reet N, Kaiser M, Karhemere Bin Shamamba S, Büscher P, PLoS Negl Trop Dis 2011 5 1025 10.1371/journal.pntd.0001025 21526217
24. The genome sequence of Trypanosoma brucei gambiense, causative agent of chronic human African trypanosomiasis. Jackson AP, Sanders M, Berry A, McQuillan J, Aslett MA, Quail MA, Chukualim B, Capewell P, MacLeod A, Melville SE, et al. PLoS Negl Trop Dis 2010 4 658 10.1371/journal.pntd.0000658 20404998
25. Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-alfa-difluoromethylornithine (DFMO). Iten M, Matovu E, Brun R, Kaminsky R, Trop Med Parasitol 1995 46 190 194 8533023
26. The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Raz B, Iten M, Grether-Buhler Y, Kaminsky R, Brun R, Acta Trop 1997 68 139 147 10.1016/S0001-706X(97)00079-X 9386789 (Pubitemid 27438330)
27. Chemotherapy of human african trypanosomiasis. Bacchi CJ, Interdiscip Perspect Infect Dis 2009 2009 195040 19707529
28. Trypanosoma brucei gambiense: HMI-9 medium containing methylcellulose and human serum supports the continuous axenic in vitro propagation of the bloodstream form. Van Reet N, Pyana PP, Deborggraeve S, Büscher P, Claes F, Exp Parasitol 2011 128 285 290 10.1016/j.exppara.2011.02.018 21354143
29. Murine models for Trypanosoma brucei gambiense disease progression-from silent to chronic infections and early brain tropism. Giroud C, Ottones F, Coustou V, Dacheux D, Biteau N, Miezan B, Van Reet N, Carrington M, Doua F, Baltz T, PLoS Negl Trop Dis 2009 3 509 10.1371/journal.pntd.0000509 19721701
30. In vitro drug sensitivity of Trypanosoma gambiense isolates. Brun R, Baeriswyl S, Kunz C, Acta Trop 1989 46 369 376 10.1016/0001-706X(89)90049-1 2575872 (Pubitemid 20083561)
31. Propidium iodide-based methods for monitoring drug action in the Kinetoplastidae: comparison with the Alamar Blue assay. Gould MK, Vu XL, Seebeck T, de Koning HP, Anal Biochem 2008 382 87 93 10.1016/j.ab.2008.07.036 18722997
32. In vitro effect of alkaloids on bloodstream forms of Trypanosoma brucei and T. congolense. Merschjohann K, Sporer F, Steverding D, Wink M, Planta Med 2001 67 623 627 10.1055/s-2001-17351 11582539 (Pubitemid 32929572)
33. Plasmodium falciparum: development of a transgenic line for screening antimalarials using firefly luciferase as the reporter. Cui L, Miao J, Wang J, Li Q, Cui L, Exp Parasitol 2008 120 80 87 10.1016/j.exppara.2008.05.003 18579134
34. Validating a firefly luciferase-based high-throughput screening assay for antimalarial drug discovery. Che P, Cui L, Kutsch O, Cui L, Li Q, Assay Drug Dev Technol 2012 10 61 68 10.1089/adt.2011.0378 22050430
35. DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening. Sereno D, Roy G, Lemesre JL, Papadopoulou B, Ouellette M, Antimicrob Agents Chemother 2001 45 1168 1173 10.1128/AAC.45.4.1168-1173.2001 11257031 (Pubitemid 32230998)
36. Luciferase-expressing Leishmania infantum allows the monitoring of amastigote population size, in vivo, ex vivo and in vitro. Michel G, Ferrua B, Lang T, Maddugoda MP, Munro P, Pomares C, Lemichez E, Marty P, PLoS Negl Trop Dis 2011 5 1323 10.1371/journal.pntd.0001323 21931877
37. Improvement of the green fluorescent protein reporter system in Leishmania spp. for the in vitro and in vivo screening of antileishmanial drugs. Pulido SA, Munoz DL, Restrepo AM, Mesa CV, Alzate JF, Velez ID, Robledo SM, Acta Trop 2012 122 36 45 10.1016/j.actatropica.2011.11.015 22155571
38. Trypanocidal activity of aziridinyl nitrobenzamide prodrugs. Bot C, Hall BS, Bashir N, Taylor MC, Helsby NA, Wilkinson SR, Antimicrob Agents Chemother 2010 54 4246 4252 10.1128/AAC.00800-10 20679506
39. In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds. Canavaci AM, Bustamante JM, Padilla AM, Perez Brandan CM, Simpson LJ, Xu D, Boehlke CL, Tarleton RL, PLoS Negl Trop Dis 2010 4 740 10.1371/journal.pntd.0000740 20644616
40. Bioluminescent imaging of Trypanosoma brucei shows preferential testis dissemination which may hamper drug efficacy in sleeping sickness patients. Claes F, Vodnala SK, Van Reet N, Boucher N, Lunden-Miguel H, Baltz T, Goddeeris BM, Büscher P, Rottenberg ME, PLoS Negl Trop Dis 2009 3 486 10.1371/journal.pntd.0000486 19621071
41. Preclinical assessment of the treatment of second-stage African trypanosomiasis with cordycepin and deoxycoformycin. Vodnala SK, Ferella M, Lunden-Miguel H, Betha E, Van Reet N, Amin DN, Oberg B, Andersson B, Kristensson K, Wigzell H, et al. PLoS Negl Trop Dis 2009 3 495 10.1371/journal.pntd.0000495 19652702
42. Inhibition of dengue virus by targeting viral NS4B protein. Xie X, Wang QY, Xu HY, Qing M, Kramer L, Yuan Z, Shi PY, J Virol 2011 85 11183 11195 10.1128/JVI.05468-11 21865382
43. A novel multiplex cell viability assay for high-throughput RNAi screening. Gilbert DF, Erdmann G, Zhang X, Fritzsche A, Demir K, Jaedicke A, Muehlenberg K, Wanker EE, Boutros M, PLoS One 2011 6 28338 10.1371/journal.pone. 0028338 22162763
44. Transformation of monomorphic and pleomorphic Trypanosoma brucei. McCulloch R, Vassella E, Burton P, Boshart M, Barry JD, Methods Mol Biol 2004 262 53 86 14769956
45. How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness? Mumba Ngoyi D, Lejon V, Pyana P, Boelaert M, Ilunga M, Menten J, Mulunda JP, Van Nieuwenhove S, Muyembe Tamfum JJ, Büscher P, J Infect Dis 2010 201 453 463 10.1086/649917 20047500
46. Isolation of salivarian trypanosomes from man and other mammals using DEAE-cellulose. Lanham SM, Godfrey DG, Exp Parasitol 1970 28 521 534 10.1016/0014-4894(70)90120-7 4993889
47. Trypanosoma brucei: A rapid "matching" method for estimating the host's parasitemia. Herbert WJ, Lumsden WHR, Exp Parasitol 1976 40 427 431 10.1016/0014-4894(76)90110-7 976425
48. Establishment of a panel of reference Trypanosoma evansi and Trypanosoma equiperdum strains for drug screening. Gillingwater K, Büscher P, Brun R, Vet Parasitol 2007 148 114 121 10.1016/j.vetpar.2007.05.020 17624671 (Pubitemid 47126741)
49. Highly efficient stable transformation of bloodstream forms of Trypanosoma brucei. Burkard G, Fragoso CM, Roditi I, Mol Biochem Parasitol 2007 153 220 223 10.1016/j.molbiopara.2007.02.008 17408766 (Pubitemid 46654247)
50. Complete in vitro life cycle of Trypanosoma congolense: development of genetic tools. Coustou V, Guegan F, Plazolles N, Baltz T, PLoS Negl Trop Dis 2010 4 618 10.1371/journal.pntd.0000618 20209144